Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M246,411Revenue $M53,634Net Margin (%)39.1Altman Z-Score4.3
Enterprise Value $M251,603EPS $4.1Operating Margin %20.9Piotroski F-Score6
P/E(ttm)25.8Beneish M-Score-2.8Pre-tax Margin (%)22.9Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %1.3Quick Ratio1.2Cash flow > EarningsY
Price/Sales4.75-y EBITDA Growth Rate %-0.6Current Ratio1.4Lower Leverage y-yN
Price/Free Cash Flow24.3y-y EBITDA Growth Rate %14.2ROA % (ttm)16.4Higher Current Ratio y-yY
Dividend Yield %2.6PEG--ROE % (ttm)29.1Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M2,399ROIC % (ttm)11.6Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2015-03-31 Reduce-0.02%$91.67 - $103
($98.99)
$ 102.734%Reduce 0.58%50,032,795
NVSTweedy Browne 2015-03-31 Reduce-0.01%$91.67 - $103
($98.99)
$ 102.734%Reduce 2.19%260,217
NVSHOTCHKIS & WILEY 2015-03-31 Sold Out -0.0031%$91.67 - $103
($98.99)
$ 102.734%Sold Out0
NVSMario Gabelli 2015-03-31 Add$91.67 - $103
($98.99)
$ 102.734%Add 2.61%9,840
NVSKen Fisher 2015-03-31 Reduce$91.67 - $103
($98.99)
$ 102.734%Reduce 0.29%5,990,224
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 102.7311%Sold Out0
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 102.7314%Reduce 98.51%9,646
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 102.7314%New holding7,772
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 102.7317%Reduce 71.80%649,519
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 102.7317%Add 10.04%51,102,219
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 102.7339%Sold Out0
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 102.7341%Sold Out0
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 102.7351%Reduce 85.39%726,200
NVSKahn Brothers 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 102.7351%Reduce 21.03%33,456
NVSVanguard Health Care Fund 2012-12-31 Reduce-0.99%$58.97 - $63.96
($61.82)
$ 102.7366%Reduce 70.59%1,461,400
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 102.7366%Add 2.65%48,438,459
NVSKahn Brothers 2012-12-31 Add0.04%$58.97 - $63.96
($61.82)
$ 102.7366%Add 10.43%42,368
NVSHOTCHKIS & WILEY 2012-12-31 Reduce-0.02%$58.97 - $63.96
($61.82)
$ 102.7366%Reduce 1.98%2,313,613
NVSKen Fisher 2012-12-31 Reduce-0.01%$58.97 - $63.96
($61.82)
$ 102.7366%Reduce 0.93%5,038,879
NVSChris Davis 2012-12-31 Reduce$58.97 - $63.96
($61.82)
$ 102.7366%Reduce 0.09%33,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15584.87view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
      8 Top Healthcare Stocks to Watch May 13 2015 
      Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
      Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
      Amgen’s Q1 Earnings Paints An Overall Positive Image To Investors Apr 22 2015 
      In Europe Really Recovering? Apr 19 2015 
      Amgen’s First Drug For Cardiovascular Disease Gets The Green Light Apr 17 2015 
      Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
      Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 

      More From Other Websites
      Here’s Why Novartis Is Expected To See Soaring Top-Line Growth May 29 2015
      How to Trade 5 Big Stocks for Big Gains -- Must-See Charts May 29 2015
      Helping your own immune system fight cancer May 28 2015
      Early movers: TIF, KORS, TOL, BWS, HRL & more May 27 2015
      Novartis digs into health tech with bet on "robotic pill" May 27 2015
      Novartis digs into health tech with bet on 'robotic pill' May 27 2015
      Novartis digs into health tech with bet on "robotic pill" May 27 2015
      Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA » May 27 2015
      Pharma Trumps All Healthcare Sectors In Executive Compensation May 26 2015
      Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog May 22 2015
      Novartis' Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel May 22 2015
      Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced... May 21 2015
      Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 » May 20 2015
      Buckingham's Top Four New Buys of First Quarter Go Up in Price May 15 2015
      Why Clovis is Getting Clobbered May 15 2015
      Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company? May 14 2015
      Possible Investment Contest May 13 2015
      GSK's Curious Oncology Research Position -- A Recipe For Failure? May 12 2015
      Novartis' Zykadia Approved in the EU for Lung Cancer - Analyst Blog May 11 2015
      ​Amgen wins injunction against Novartis' biosimilar drug May 08 2015
      Pharmalot.. Pharmalittle.. As the Weekend Nears: We're Catching up on Amgen, Sanofi and Much More!! May 08 2015
      Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients... May 08 2015
      [$$] Business Watch: News Digest May 08 2015
      Novartis 'biosimilar' drug blocked by U.S. appeals court May 07 2015
      Glaxo's (GSK) Q1 Earnings Fall Y/Y; Gives Five-Year View - Analyst Blog May 07 2015
      Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court May 07 2015
      Court Blocks Novartis Copy of Amgen Cancer-Care Drug May 07 2015
      Today's Top 5 Stock Picks: Undervalued Large-Caps May 06 2015
      GlaxoSmithKline opts to hold on to HIV business May 06 2015
      GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
      GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
      GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
      GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
      GSK cuts Novartis payout as first-quarter revenues rise but earnings ease May 06 2015
      GlaxoSmithKline plc Pleases The Market With New Strategic 5-Year Plan May 06 2015
      Drugs giant GSK says net profits soar May 06 2015
      New-look GSK bets on consumer health spending May 06 2015
      Interview - New-look GSK bets on consumer health spending May 06 2015
      Interview - New-look GSK bets on consumer health spending May 06 2015
      Drugs giant GSK says net profits soar May 05 2015
      Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
      Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
      Doubts grow over GlaxoSmithKline's 4 billion pound capital return plan May 01 2015
      Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
      ImmunoGen skids after disclosing drug development setbacks Apr 27 2015
      Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free... Apr 27 2015
      Novartis CEO Joseph Jimenez Nominated to GM Board Apr 24 2015
      Novartis keeps full-year target as Q1 earnings fall Apr 23 2015
      Novartis posts Q1 profit beat despite dollar drag Apr 23 2015
      Novartis posts Q1 profit beat despite dollar drag Apr 23 2015
      Divestment gains boost net earnings at drug company Novartis Apr 23 2015
      Novartis warns of currency drag on 2015 earnings Apr 23 2015
      Novartis confirms 2015 guidance after first-quarter profit beat Apr 23 2015
      Novartis confirms 2015 guidance after Q1 profit beat Apr 23 2015
      Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1;... Apr 23 2015
      Novartis keeps full-year target as Q1 earnings fall Apr 22 2015
      CSL's CFO to head flu vaccines business Apr 22 2015
      Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in... Apr 21 2015
      FDA approves generic version of top-selling MS drug Copaxone Apr 17 2015
      Aduro Biotech Establishes Major Collaboration with Novartis for Global Research, Development and... Apr 17 2015
      Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone®... Apr 16 2015
      FDA approves new type of heart failure drug from Amgen Apr 15 2015
      Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free... Apr 15 2015
      Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods... Apr 13 2015
      Global generic drugs market sees FDA approve new type of generic drugs made from living cells Mar 30 2015
      Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with... Mar 30 2015
      Novartis digs deeper into cancer with up to $750 million Aduro deal Mar 30 2015
      Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new... Mar 30 2015
      GSK agrees UK deal for meningitis shot after Novartis stand-off Mar 29 2015
      Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in... Mar 21 2015
      New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI... Mar 20 2015
      Novartis unit hit with $110 million gender discrimination suit Mar 17 2015
      Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for... Mar 17 2015
      GSK and Novartis complete deals to reshape both drugmakers Mar 02 2015
      GSK and Novartis complete deals to reshape both drugmakers Mar 02 2015
      GSK and Novartis complete deals to reshape both drugmakers Mar 02 2015
      GSK set to complete 13 billion pounds Novartis asset swap next week Feb 25 2015
      GSK set to complete $20 bln Novartis asset swap next week Feb 25 2015
      FDA approves Novartis drug for bone marrow cancer Feb 23 2015
      Novartis AG wins approval to buy GSK cancer drugs, with conditions Feb 23 2015
      Australian regulator says will not oppose GSK, Novartis deals Feb 19 2015
      EU puts conditions on deals involving Novartis, GSK Jan 28 2015
      EU clears plans by drugmakers GSK and Novartis to trade assets Jan 28 2015
      EU clears GSK's acquisition of Novartis vaccines with conditions Jan 28 2015
      EU clears Novartis to buy GSK's oncology business with conditions Jan 28 2015
      Novartis profits jump 12% on new drug sales Jan 27 2015
      Novartis sues Cipla over respiratory drug Onbrez Dec 17 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK